Cabotegravir▼ and rilpivirine▼ implementation study in European locations (CARISEL) study

100%
100%
na

CARISEL: Patient Identification

The CARISEL study explored the level of support needed to successfully implement CAB+RPV LA in European clinics. This video provides a summary of the CARISEL provider data on the wide variety of patients that CAB+RPV may be suitable for from a recent study publication in the Journal of the International AIDS Society.

 

na

CARISEL: Key Clinical Implementation Components

The CARISEL study explored the level of support needed to successfully implement CAB+RPV LA in European clinics. The second video here provides a summary of the key components that different European clinics used to provide CAB+RPV LA successfully.

 

View CARISEL congress posters

  • Optimizing the clinic flow process for integration of cabotegravir + rilpivirine long-acting into routine care: findings from cabotegravir and rilpivirine implementation study in european locations (carisel)
    Presented at IAS 2023
    Read more
  • Effectiveness, safety, and implementation outcomes of cabotegravir + rilpivirine long-acting by country in the cabotegravir and rilpivirine implementation study in european locations (carisel)
    Presented at EACS 2023
    Read more
  • Cabotegravir + rilpivirine long-acting effectiveness and safety outcomes by sex at birth, age, and race: A subgroup analysis of the carisel study
    Presented at EACS 2023
    Read more
  • Safety and effectiveness outcomes from the carisel study: Phase 3B hybrid-3 implementation study integrating cabotegravir + rilpivirine long-acting into european clinical settings
    Presented at AIDS 2022
    Read more
  • Perspectives on the acceptability, appropriateness, feasibility, barriers, and facilitators from patients receiving cabotegravir+ rilpivirine long acting injectable treatment (CAB +RPV LA): Interim results from the cabotegravir and rilpivirine implementation study in european locations (carisel)
    Presented at EACS 2021
    Read more
  • Healthcare staff perspectives on the implementation of HIV injectable treatment: Interim results from the cabotegravir and rilpivirine implementation study in european locations (carisel)
    Presented at EACS 2021
    Read more
  • Cabotegravir and rilpivirine implementation study in european locations (carisel): Examining healthcare staff attitudes during a hybrid III implementation-effectiveness trial implementing cabotegravir + rilpivirine long-acting injectable (CAB +RPV LA) for people living with HIV
    Presented at EACS 2021
    Read more

NP-GBL-HVX-WCNT-240022 October 2024

Report an adverse event

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221441.

If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.